| Incremental cost‐effectiveness ratio | |||||
|---|---|---|---|---|---|
| Study | Group | TC | TG | LDL‐C | HDL‐C |
| Xuezhikang versus pravastatin | |||||
| Wang 2003 | Xuezhikang group | 100 | 100 | 100 | 100 |
| Wang 2003 | Pravastatin group | 135.75 | 338.84 | 141.56 | 93.01 |
| Incremental cost‐effectiveness ratio | |||||
|---|---|---|---|---|---|
| Study | Group | TC | TG | LDL‐C | HDL‐C |
| Xuezhikang versus pravastatin | |||||
| Wang 2003 | Xuezhikang group | 100 | 100 | 100 | 100 |
| Wang 2003 | Pravastatin group | 135.75 | 338.84 | 141.56 | 93.01 |